After a Speedy IPO, Equillium Expands Antibody R&D to Renal Disease
Xconomy
FEBRUARY 28, 2019
Equillium, a biotech that’s looking to develop an antibody drug for immuno-inflammatory diseases, has added a form of renal disease to the indications for which it aims to develop medicines. Equillium was formed to advance. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.
Let's personalize your content